Answers are grounded in this paper and cite their sources.
BACKGROUND: Anthracycline (A) and taxane (T)-based therapies improve breast cancer survival, with guidelines strongly recommending these regimens and dose-dense approaches. However, the real-world maintenance of optimal dose intensity, a critical prognostic factor, remains unclear. We aimed to clarify the current treatment situation regarding relative dose intensity (RDI), with a secondary focus on safety. METHODS: In this retrospective observational study, we analyzed big data from the DATuM IDEA® electronic medical record database of the Japan Medical Association Medical Information Management Organization, collected from 1 206 955 individuals across 53 medical institutions throughout Japan over 57 months since 2019. We focused on women with primary breast cancer receiving adriamycin/cyclophosphamide (AC), epirubicin/cyclophosphamide (EC), or docetaxel/cyclophosphamide chemotherapy (TC). RESULTS: Analysis included 1989 women who received at least two courses of AC, EC, or TC perioperatively. Patients received 2-weekly adriamycin/cyclophosphamide (ddAC) (n = 207), 3-weekly AC (AC q3w) (n = 177), 2-weekly epirubicin/cyclophosphamide (ddEC) (n = 269), 3-weekly EC (EC q3w) (n = 684), and TC (n = 652). Pegfilgrastim was administered to 98% of ddAC/ddEC, 38% of AC q3w, 42% of EC q3w, and 74% of TC patients. Grade 4 neutropenia (incidences >20%) was observed in AC q3w patients aged ≥65 years (22.6%) and in TC patients of any age (27.6%). RDI remained >95% in all groups. CONCLUSIONS: RDI was high in all groups. Clinicians should be cautious when administering AC q3w therapy owing to the high likelihood of patients developing Grade 4 neutropenia. For TC, a slightly lower pegfilgrastim administration rate and >20% Grade 4 neutropenia suggest the need for appropriate pegfilgrastim use.
No takes yet. Share an insight, caveat, or question.
Kawai et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: